Talk:Natco Pharma

This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:

Companies Companies portal This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks. ??? This article has not yet received a rating on the project's importance scale. WikiProject Companies To-do: Here are some tasks awaiting attention: Article requests : Wikipedia:Requested articles/Business and economics/Companies Assess : Category:Unassessed company articles Copyedit : Category:Company articles needing attention Infobox : Category:Company articles needing infoboxes Maintain : Portal:Companies Stubs : Help expand stub articles located at Category:Company stubs Other : Tag company articles with the {{portal|Companies}} template Tag company talk pages with the {{WikiProject Companies}} project banner Answer requests for comments

PR tag

Prolix, could you explain the PR tag? The content is factual, neutral and backed by independent, reliable and secondary sources. Here are WP:THREE sources to prove notability: [1] [2] [3]. FYI, there were Wikipedia articles in over a dozen other languages before I created the English version earlier this year. If you still have "questions" about its notability, please start an AFD. M4DU7 (talk) 08:39, 28 December 2020 (UTC)[reply]

Hello, just a gentle follow-up on my edit request above.

The proposed changes are fully sourced and intended to update outdated information.

Thank you for your time and consideration. Markcreatives (talk) 06:01, 22 January 2026 (UTC)[reply]

Paid/COI disclosure:

I disclose that I run a creative agency and am assisting a personal contact who works at Natco Pharma with drafting proposed Wikipedia edit requests. I am not an employee of Natco Pharma and will not edit the article directly. I will only submit edit requests on talk pages in accordance with WP:COI and WP:EDITREQUEST. MarkContributor (talk) 06:33, 28 January 2026 (UTC)[reply]

Conflict of interest & edit request

I would like to disclose a conflict of interest, as I am connected with the subject of this article. I am requesting changes through the talk page in accordance with Wikipedia’s conflict of interest guidelines.

Edit request: Update lead, history, businesses and CSR sections

I am requesting an update to the Natco Pharma article using reliable published sources. Below is the proposed replacement text written in neutral encyclopedic tone, with inline citations.

Proposed text

Natco Pharma is an Indian multinational vertically integrated pharmaceutical company based in Hyderabad, Telangana. The company operates in pharmaceutical formulations, active pharmaceutical ingredients (APIs) and agrochemical products in domestic and international markets.[1] It is a major producer of branded oncology medicines and also operates in cardiology, diabetology and other specialty therapeutic areas.[2][3] During the early 2000s, advances in cancer screening, diagnosis, molecular pathology, targeted therapies, immunotherapies and supportive care significantly improved outcomes globally. However, the high cost of targeted therapies limited accessibility in many developing countries. Through in-house research and development, Natco Pharma developed generic versions of several targeted and specialty therapies, enabling wider access at substantially lower cost.[4] The company launched its first affordable targeted therapy in India in 2003. Research and development continues to be a core component of its operations, supporting the development of complex generic medicines and selected drug discovery initiatives.[5] == History == Natco Pharma was founded in 1981 by Venkaiah Choudary Nannapaneni with the objective of improving access to specialty medicines.[6] 1981 – Commenced formulation manufacturing at its Kothur facility. 1986 – Began manufacturing parenteral products at the Nagarjuna Sagar facility. 1992 – Natco Pharma was listed as a public company on 1 July 1992. 1993 – Chemical division at Mekaguda, Telangana commenced production of APIs and intermediates. 2003 – Launched its oncology division with the introduction of VEENAT (generic imatinib mesylate) for chronic myelogenous leukemia. 2009 – Established an organics facility in Chennai for cytotoxic APIs and biotechnology products. 2011 – Incorporated its Brazilian subsidiary, NATCO Farma do Brasil LTDA. 2013 – Established Natco Pharma Canada Inc. for sales and distribution in Canada. 2016 – Launched a generic version of oseltamivir phosphate capsules in the United States.[7] 2017 – Entered cardiology and diabetology segments in India with the launch of dabigatran. 2017 – Launched glatiramer acetate injection and liposomal doxorubicin in the United States.[8] 2019 – Established the Crop Health Sciences division.[9] 2022 – Launched the first generic version of Revlimid in the United States. 2022 – Introduced chlorantraniliprole (CTPR)-based agrochemical products in India. 2023 – Established subsidiaries in Indonesia and Colombia to expand international operations. 2024 – Invested in Cellogen Therapeutics Pvt. Ltd. and eGenesis for cell, gene therapy and xenotransplantation initiatives. == Businesses == Natco Pharma operates through two primary business segments: pharmaceuticals and agrochemicals. === Pharmaceuticals === The pharmaceutical business comprises finished dosage formulations (FDF) and active pharmaceutical ingredients (API), supplying products to more than 50 markets including the United States, Canada, Brazil, Australia, the Middle East, North Africa and Asia Pacific regions.[10] ==== Export formulations ==== The export formulations business focuses on niche and complex pharmaceutical products across regulated international markets. ==== Domestic formulations ==== Natco’s domestic pharmaceutical operations are segmented into oncology, pharma specialties, cardiology and diabetology.[11] === Active pharmaceutical ingredients === Natco’s API business supports captive consumption and external customer supply and covers multiple therapeutic areas including oncology, central nervous system disorders, pain management and cardiovascular treatments.[12] === Crop Health Sciences === The Crop Health Sciences division develops agrochemical and biological crop solutions and introduced chlorantraniliprole-based insecticide products and pheromone-based pest control solutions for pink bollworm management.[13] == Corporate social responsibility == Corporate social responsibility initiatives are undertaken through the Natco Trust, established in 1995, operating in Telangana and Andhra Pradesh with programmes in education, healthcare, sanitation and livelihood generation.[14] References "Our Business | Natco Pharma". Retrieved 25 April 2022. "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020. "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020. "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020. "Mission & Heritage | Natco Pharma". Retrieved 25 April 2022. "Natco Pharma Ltd – History of Company". Retrieved 8 January 2026. "Bayer cancer drug faces new Nexavar patent problems in India". Retrieved 3 February 2022. "Niche Play". Business Today. Retrieved 19 April 2020. "Natco Pharma expects agri business to be key growth lever". The Hindu Business Line. 25 November 2020. Retrieved 24 April 2022. Rishav Kaushik (2 July 2025). "Natco Pharma – Betting on the Jockey". Sana Securities. Retrieved 19 January 2026. Rishav Kaushik (2 July 2025). "Natco Pharma – Betting on the Jockey". Sana Securities. Retrieved 19 January 2026. "Natco Pharma Limited – Ratings reaffirmed and assigned for enhanced amount". ICRA Limited. 28 November 2025. Retrieved 19 January 2026. Rahul Koul (12 May 2021). "NATCO Pharma bets big on agrochemical". Indian Chemical News. Retrieved 19 January 2026. "Corporate Social Responsibility Policy" (PDF). Natco Pharma Limited. 2025. Retrieved 19 January 2026.

Thank you for reviewing this request. Markcreatives (talk) 10:59, 19 January 2026 (UTC)[reply]

This edit request has been answered. Set the |answered= parameter to no to reactivate your request.

== Edit request: Add Corporate social responsibility section ==

Please consider adding the following sourced text under a new section titled "Corporate social responsibility":

Corporate social responsibility initiatives are undertaken through the Natco Trust, established in 1995, operating in Telangana and Andhra Pradesh with programmes in education, healthcare, sanitation and livelihood generation.

Source:

^[1]

Thank you. Markcreatives (talk) 05:18, 23 January 2026 (UTC)[reply]

 Not done: {{edit request}} is for requesting edits to semi-protected pages. For a conflict of interest request, please use {{Edit COI}}. GearsDatapack (talk) 09:48, 23 January 2026 (UTC)[reply]

Thank you for pointing that out.

You are correct — this request should be handled as a conflict-of-interest edit request.

I have now resubmitted the request below using the appropriate

The user below has a request that an edit be made to Natco Pharma. That user has an actual or apparent conflict of interest. The requested edits backlog is very high. Please be extremely patient. There are currently 338 requests waiting for review. Please read the instructions for the parameters used by this template for accepting and declining them, and review the request below and make the edit if it is well sourced, neutral, and follows other Wikipedia guidelines and policies.

template.

I appreciate your guidance and patience.

— MarkContributor (talk) MarkContributor (talk) 13:50, 29 January 2026 (UTC)[reply]

Edit request: Add Corporate social responsibility section

Please consider adding the following sourced sentence under a new section titled “Corporate social responsibility”: Text to add:

“Corporate social responsibility initiatives are undertaken through the Natco Trust, established in 1995, operating in Telangana and Andhra Pradesh with programmes in education, healthcare, sanitation and livelihood generation.”

Source:

Natco Pharma Limited (2025). Corporate Social Responsibility Policy (PDF).

I am submitting this as a single, specific request and welcome feedback before proposing any further incremental updates. MarkContributor (talk) 06:33, 28 January 2026 (UTC)[reply]

Hello, just a gentle follow-up on the edit request above.

This is a small, single-sentence addition with a cited source.

Whenever convenient, I would appreciate a review.

Thank you for your time.

— MarkContributor (talk) MarkContributor (talk) 13:46, 29 January 2026 (UTC)[reply]

1. "Corporate Social Responsibility Policy" (PDF). Natco Pharma Limited. 2025. Retrieved 22 January 2026.